Get the Stockscreener App
36.85
0.12%
0.045
Bridgebio Pharma Inc stock is traded at $36.85, with a volume of 2.42M.
It is up +0.12% in the last 24 hours and up +2.13% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$36.80
Open:
$37.94
24h Volume:
2.42M
Relative Volume:
0.95
Market Cap:
$6.96B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-15.29
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+5.59%
1M Performance:
+2.13%
6M Performance:
+44.17%
1Y Performance:
+7.87%
1-Day Range:
$36.38
$38.05
1-Week Range:
$33.86
$39.47
52-Week Range:
$21.62
$39.47
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
36.85 | 6.96B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio price target raised to $52 from $49 at Scotiabank - Yahoo Finance
BridgeBio Pharma Q4 2024 Earnings: Revenue Surpasses Estimates a - GuruFocus.com
BridgeBio: Strong Commercial Momentum for Attruby Sets the Stage for Long-Term Profitability - Morningstar
BridgeBio’s Attruby Off To A Strong Start – But Alnylam Awaits - News & Insights
BridgeBio Pharma Reports Strong 2024 Financial Results - TipRanks
BridgeBio Pharma, Inc. SEC 10-K Report - TradingView
BridgeBio: Strong Start For Attruby (NASDAQ:BBIO) - Seeking Alpha
BridgeBio’s stock rises on promising sales of recently approved heart drug - MM+M Online
BridgeBio’s heart drug launch gets off to a fast start - BioPharma Dive
BridgeBio Pharma stock hits 52-week high at $39.23 - Investing.com
Risky weight loss, grad school acceptance cuts, and more major biotech news of the day - STAT
BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
BridgeBio Pharma earnings missed by $0.27, revenue topped estimates - Investing.com
BridgeBio Pharma Q4 Loss Widens, Revenue Rises -- Shares Up Pre-Bell -February 20, 2025 at 08:04 am EST - Marketscreener.com
BRIDGEBIO PHARMA Earnings Results: $BBIO Reports Quarterly Earnings - Nasdaq
BridgeBio Pharma: Q4 Earnings Snapshot - The Bakersfield Californian
Earnings Flash (BBIO) BridgeBio Pharma Posts Q4 Revenue $5.9M, vs. FactSet Est of $3.1M - Marketscreener.com
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update - TradingView
BridgeBio Pharma CFO Brian Stephenson sells $149,973 in stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Neil Kumar sells $1.14 million in stock By Investing.com - Investing.com Nigeria
BridgeBio Pharma CEO Neil Kumar sells $1.14 million in stock - Investing.com India
BridgeBio Pharma CFO Brian Stephenson sells $149,973 in stock - Investing.com India
Earnings Flash (BBIO) BridgeBio Pharma Posts Q4 Net Loss $-1.40 a Share, vs. FactSet Est of $-1.13 Loss - Marketscreener.com
Market Whales and Their Recent Bets on BBIO Options - Benzinga
Why Is BridgeBio Pharma Stock Trading Higher On Friday? - MSN
Piper Sandler maintains $46 target on BridgeBio stock after survey - Investing.com India
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 7.2%What's Next? - MarketBeat
Scotiabank Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
(BBIO) Trading Signals - Stock Traders Daily
Harvey Capital Management Inc. Takes $354,000 Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
HC Wainwright Reaffirms Buy Rating for BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma to Report Fourth Quarter and Full Year - GlobeNewswire
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 - The Manila Times
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February - EIN News
BridgeBio price target raised to $49 from $48 at Scotiabank - Yahoo Finance
BridgeBio Pharma’s European Approval of Acoramidis and Strong Pipeline Justifies Buy Rating - TipRanks
BridgeBio’s receives EU approval for its Transthyretin Amyloidosis treatment - MSN
BridgeBio shares rise on Scotiabank price target boost - MSN
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment - MSN
BridgeBio shares rise on Scotiabank price target boost By Investing.com - Investing.com South Africa
BridgeBio gets EU nod for ATTR cardiomyopathy drug - pharmaphorum
BridgeBio Pharma Announces EU Approval Of BEYONTTRA For Treatment Of ATTR-CM - Nasdaq
BridgeBio wins EU approval for Beyonttra for ATTR-CM - The Pharma Letter
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis - Marketscreener.com
BridgeBio announces EC marketing authorization for BETONTTRA - TipRanks
BEYONTTRA™ (acoramidis), the First Near Complete TTR - GlobeNewswire
BBIO Secures Major EU Win: Revolutionary Heart Drug Shows 42% Mortality Reduction - StockTitan
BridgeBio's Heart Disease Drug Meets Late-stage End Points - BW Healthcare World
Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts - Insider Monkey
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Feb 19 '25 |
Sale |
36.14 |
31,543 |
1,140,024 |
211,718 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):